Indian Pharmaceutical Supplier to Uzbekistan.

Substantively. Before 2017, hard-currency convertibility was restricted, repatriation of export proceeds was uncertain, foreign direct investment in pharmacy retail was effectively closed, and tenders were opaque. The Mirziyoyev reform package restored UZS convertibility, liberalised foreign investment, privatised pharmacy retail (creating Pharmamed and Lubmedfarm chains), and rewrote the public procurement rules. India became a top-three supplier within three years.

Both. We supply Pharmamed and Lubmedfarm retail and a network of private importers on commercial terms, and we work with locally registered tender agents to participate in Uzpharminvest, Ministry of Health vertical-programme, and Tashkent Health Department bids. The structure is always foreign manufacturer plus local agent of record. We provide the dossier, the GMP backing, the Russian-language bid sheet, and the supply commitment; the agent handles the local-entity tender filing.

Plan for 10 to 16 months end to end for a standard generic, which is faster than Kazakhstan in our experience. The active review window is around 180 working days; the rest is Russian-language dossier preparation, notarised translation, sample testing at an Uzbek laboratory, and review queries. Reform-era turnover at UzPharm means relationships matter: our Tashkent consultant maintains direct contact with reviewers and we route review queries through that channel to keep response times tight.

Yes, and it is the structural reason Uzbekistan is one of the easier Central Asian destinations for cold-chain medicines. Uzbekistan Airways and Air India both run direct wide-body cargo from Mumbai to Tashkent on a four-hour flight, which keeps the temperature exposure window short. We use temperature-mapped envirotainers with dual data loggers as standard, and our Tashkent customs broker is briefed to clear within four hours of touchdown. Redundancy lane is BOM-DXB-TAS for capacity tightness.

The State Bank of India operates a full branch in Tashkent, which is genuinely unusual outside India's immediate neighbourhood and reflects the depth of India-Uzbekistan SCO trade ties. SBI Tashkent supports INR and USD clearing directly without correspondent friction. We use INR settlement for around a third of our Uzbek invoices, particularly for tenders that prefer rupee-denominated bids and importers with INR receivables from other Indian exposure. USD remains the default for most of the rest. Hamkor Bank handles UZS convertibility on the local leg.

Russian is the working language of UzPharm review and Uzpharminvest tender documentation, and it is what we prepare against. Uzbek is the official state language and increasingly used at the working level since the reforms; outer-carton labelling and patient information leaflets need bilingual Russian-Uzbek copy, which we coordinate through certified Tashkent translators. English dossiers are accepted with notarised Russian translation but we recommend native Russian preparation from draft one to avoid the rejection cycle.

It is the right question and the answer is yes if you take a three-year view. Population is 37 million and growing at over 2 percent, faster than most CIS markets. Chronic-disease prescribing is rising 12 to 15 percent year on year as the post-reform middle class expands. India is already a top-three supplier and gaining share. The absolute market size is smaller than Kazakhstan today, but the growth rate, the favourable banking and SCO trade environment, and the direct freight lane combine to give a stronger three-year compounding return on the registration investment.